SERCA and P-glycoprotein inhibition and ATP depletion are necessary for celastrol-induced autophagic cell death and collateral sensitivity in multidrug-resistant tumor cells-Reference-Cited by-同舟云学术

SERCA and P-glycoprotein inhibition and ATP depletion are necessary for celastrol-induced autophagic cell death and collateral sensitivity in multidrug-resistant tumor cells

Published:2020-03 Issue: Volume:153 Page:104660
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Xu Su-Wei,Law Betty Yuen Kwan,Qu Steven Li Qun,Hamdoun Sami,Chen Juan,Zhang Wei,Guo Jian-Ru,Wu An-Guo,Mok Simon Wing Fai,Zhang David Wei,Xia Chenglai,Sugimoto Yoshikazu,Efferth Thomas,Liu Liang,Wong Vincent Kam Wai

Funder

Macao Science and Technology Development Fund

Foshan Medicine Dengfeng Project of China

Publisher

Elsevier BV

Subject

Pharmacology

Reference85 articles.

1. Cancer drug resistance: an evolving paradigm;Holohan;Nat. Rev. Cancer,2013

2. Circumventing cancer drug resistance in the era of personalized medicine;Garraway;Cancer Discov.,2012

3. Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells;Ajabnoor;Cell Death Dis.,2012

4. Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells;Branch;Oncogene,2000

5. Mechanisms of cancer drug resistance;Gottesman;Annu. Rev. Med.,2002

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Herbal Therapies for Cancer Treatment: A Review of Phytotherapeutic Efficacy;Biologics: Targets and Therapy;2024-09

2. Combination therapy using Cel-CSO/Taxol NPs for reversing drug resistance in breast cancer through inhibiting PI3K/AKT/NF-κB/HIF-1α pathway;Drug Delivery and Translational Research;2024-06-26

3. Amorphous CaCO3-bioreactor for tumor microenvironment regulation to reinforce tumor chemoimmunotherapy;Chemical Engineering Journal;2024-06

4. Natural products for combating multidrug resistance in cancer;Pharmacological Research;2024-04

5. (2R,4aS,6aS,12bR,14aS,14bR)-N-(2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)ethyl)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxamide;Molbank;2024-04-01